CanCertain (formerly CLYZ Labs) is developing a testing service to select the best drug therapy for personalised cancer treatment. CanCertain will combine information on the sensitivity of the patients own tumor cells to a range of drugs along with biomarker and treatment guidelines to provide a personalised treatment recommendation. This is expected to increase life expectancy and reduce costs by selecting the best treatment option for an individual.
Why we like the business
Highly personalised cancer therapy is fast becoming the standard of care and CanCertain is well positioned to provide an fully integrated service to support clinicians to provide the best treatment and care for patients.